Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Anemia × ferric derisomaltose × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia, Iron-Deficiency 2 Anemia 1 Anaemia in Ovarian Carcinoma 1

Interventions

Epoetin Alfa 26 Darbepoetin alfa 10 epoetin beta 3 Erythropoietin 3 luspatercept 2 ferric carboxymaltose 2 Ferric Oxide, Saccharated 2 Cisplatin 2 Blood Transfusion 2 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2 telapristone acetate 1 ibrutinib 1 fludarabine phosphate 1 fludarabine 1 ferrous sulfate 1 ferric gluconate 1 ferric derisomaltose 1 fanasil, pyrimethamine drug combination 1 Taxes 1 Sugars 1 Sucrose 1 Solutions 1 Saline Solution 1 Rituximab 1 Radiotherapy 1 Pharmacogenomic Testing 1 Paclitaxel 1 Lenalidomide 1 Iron-Dextran Complex 1 Injections 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05407987 2025-04-25

FORGE II

AHS Cancer Control Alberta

Phase 3 Recruiting

Classical hematology

Anemia, Anemia, Iron-Deficiency

Data powered by HemOnc (CC BY 4.0) Colophon ⚡